Allison Brashear, M.D.
Professor and Chair
Clinical Interests: Dystonia, Botulinum toxin, Spasticity, Parkinson's disease, and Movement disorders
EDUCATION:
1979-1983 DePauw University, Greencastle, Indiana University
B.A. Degree-Chemistry
1983 – 1987 Indiana University School of Medicine, Indianapolis, IN
M.D. Degree
POST DOCTORAL TRAINING:
1987-1988 Indiana University School of Medicine, Indianapolis, IN
Department of Medicine Internship
1988 – 1991 Indiana University School of Medicine, Indianapolis, IN
Department of Neurology - Neurology Residency
PROFESSIONAL LICENSURE:
Indiana
North Carolina
SPECIALTY CERTIFICATION:
Diplomat, American Board of Medical Examiners, 1988
Diplomat, American Board of Psychiatry and Neurology, (ABPN), June, 1993
Diplomat, American Board of Electrodiagnostic Medicine (ABEM), April, 1995, recertified 9/2005
Dr. Brashear has been the principal investigator in many multi-center trials in the treatment of cervical dystonia and spasticity with botulinum toxin. She is the chair of the American Academy of Neurology/Movement Disorder Society Spasticity/Dystonia Advisory Board and directs courses at national workshops designed to teach the technique of botulinum toxin treatment.
Dr. Brashear has published numerous peer-reviewed journal articles and book chapters on topics including the use of botulinum toxin for the treatment of dystonia and spasticity. Her 2002 publication, “Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity After a Stroke” in the New England Journal of Medicine demonstrated functional improvement in patients treated with botulinum toxin for post-stroke spasticity. Dr. Brashear is the lead author on two pivotal papers on the use of botulinum toxin type B in cervical dystonia and spasticity.
Dr. Brashear is the principal clinician to describe a unique genetic form of dystonia-parkinsonism, Rapid-Onset Dystonia-Parkinsonism (RDP). The gene responsible for RDP, mutations in the Na/K ATPase α3 subunit, was reported in Neuron in July 2004.
Dr. Brashear’s work has appeared in such journals as Annals of Neurology, Neurology, Movement Disorders, Muscle and Nerve and others. Dr. Brashear is a frequent reviewer for these and other journals. Dr. Brashear is the current president of the Indiana Neurological Society, the only state-wide organization of neurologists. Dr. Brashear is a member of many professional organizations, including a fellow of the American Academy of Neurology, the American Neurological Association, the American Association of Electrodiagnostic Medicine, and the Movement Disorder Society.
Dr. Brashear graduated from Indiana University School of Medicine in 1987 and completed her training in Neurology in 1991.
Recent Publications
Book chapters:
Siemers E, Brashear A. Other Therapies. In: Factor SA, Weiner WJ (eds). Parkinson's Disease Diagnosis and Clinical Management. New York, Demos Medical Publishing, 2002;437-443.
Brashear A. “Adult Spasticity”. In: Mark LeDoux MS (eds). Animal Models of Movement Disorders. Elsevier Academic, 2005; 679-686.
Brashear, A. In: The Use of Botulinum Toxins in Clinical Medicine. Haworth Medical Press, 2006
Journal Articles:
Brashear A, McAfee A, Kuhn E, Ambrosius W. Botulinum Toxin Type B in Upper Limb Spasticity. Archives of Phys Med 2003;84:103-107.
Comella C, Leurgans S, Wuu J, Stebbins T, Chmura T and the Dystonia Study Group. Rating Scales for Dystonia: A Multicenter Assessment. Mov Disord 2003;18(3):303-312.
Brashear A. The Use of Botulinum Toxin Type A in Post-Stroke Spasticity. Expert Rev Neurotherapeutics 2003;3(3):271-277.
Brashear A, McAfee AL, Kuhn ER, and Fyfee J. A Double-Blind, Placebo-Controlled Trial of Botulinum Toxin Type B in Upper Limb Post-Stroke Spasticity. Archives of Physical Medicine and Rehabilitation 2004;85(5):705-709.
Kamm C, Leung J, Joseph S, Dobyns W, Brashear A, et al. Refined linkage to the RDP/DYT12 locus on 19q13 and evaluation of GRIK5 as a candidate gene. Movement Disorders 2004 Jul; 19(7):845-7.
Yoder K, Hutchins G, Morris E, Brashear A, et al. Dopamine Transporter Density In Schizophrenic Subjects With and Without Tardive Dyskinesia. Schizophrenia Research Dec 1,2004; 71(2-3):371-375.
Childers M, Brashear A, Jozefczk P, Reding M Glass A, Alexander D, Good D, Turkel C. Dose-dependent response to intramuscular Botulinum Toxin Type A for Upper Spasticity in Patients After a Stroke. Archives of Physical Medicine and Rehabilitation. 2004 Jul;85(7):1063-9.
Zaremba, J, Mierzewska H, Lysiak Z, Kramer P, Ozelius L J, Brashear A. Rapid –Onset Dystonia – Parkinsonism: A Fourth Family Consistent To Linkage to Chromosome 19q13. Movement Disorders 19(12):1506-1510.
De Carvalho Aguiar, P, Sweadner K, Penniston JT., Zaremba J, Liu L, Linazasoro G, Borg M, Tijssen, M, Bressman, S, Dobyns, WB, Brashear, A, Ozelius, LJ. Mutations in the Na+,K+-ATPase alpha 3 gene (ATP1A3) are associated with rapid onset dystonia parkinsonism (RDP, DYT12). Neuron 2004 July 22; 43(2): 169-75.
Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, and Turkel C.PharmD,Repeated Doses of Botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:971-1973
Brashear A, Safety and Tolerability of Botulinum toxin type A in cervical dystonia. Expert Opinion on Drug Safety, 2005;4:241-249